Who are Parecoxib and remifentanil's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/parecoxib-and-remifentanil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Parecoxib and remifentanil — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Parecoxib and remifentanil (Parecoxib and remifentanil) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: COX-2 selective inhibitor (parecoxib) and opioid agonist (remifentanil). Area: Pain Management / Anesthesia.

marketed COX-2 selective inhibitor (parecoxib) and opioid agonist (remifentanil) COX-2 (parecoxib); mu-opioid receptor (remifentanil) Pain Management / Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Parecoxib and remifentanil (Parecoxib and remifentanil) — Ullevaal University Hospital. Parecoxib is a selective COX-2 inhibitor that reduces pain and inflammation, while remifentanil is a potent opioid agonist that provides rapid analgesia and sedation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Parecoxib and remifentanil TARGET	Parecoxib and remifentanil	Ullevaal University Hospital	marketed	COX-2 selective inhibitor (parecoxib) and opioid agonist (remifentanil)	COX-2 (parecoxib); mu-opioid receptor (remifentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (COX-2 selective inhibitor (parecoxib) and opioid agonist (remifentanil) class)

Ullevaal University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Parecoxib and remifentanil — Competitive Intelligence Brief. https://druglandscape.com/ci/parecoxib-and-remifentanil. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab